PRINT OUT

Leading Products

May 13. 2019
(Â¥ million)


Brand name Active Ingredient Indications Launch
Date
Sales
2017
Sales
2018
Sales 2019(estimated)
Apr.-Sep. Annual
Vidaza azacitidine myelodysplastic syndrome Mar-2011 15,643 14,453 7,500 14,500
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 10,449 12,118 6,500 13,000
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 6,622 7,196 3,800 7,500
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 4,617 5,173 2,800 5,400
Uptravi selexipag pulmonary arterial hypertension Nov-2016 2,690 4,825 3,400 7,300
Lunabell norethisterone and ethinylestradiol dysmenorrhea Jul-2008 5,374 4,658 1,100 2,000
Cialis tadalafil erectile dysfunction Jul-2009 3,825 4,592 2,000 3,700
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,916 2,987 650 2,700
Azunol Gargle sodium gualenate pharyngitis, tonsillitis, stomatitis, etc. Aug-2002 2,363 2,169 900 2,050
Eviprostat herbal extracts benign prostatic hyperplasia Apr-1967 2,761 2,137 1,000 1,800
Gazyva obinutuzumab CD20-positive follicular lymphoma Aug-2018 - 1,417 1,600 3,500
Profit in co-promotion 3,962 5,057 2,600 5,800
Revenues from the licensing of industrial 10,378 16,621 7,800 16,800
Pharmaceuticals 87,416 100,223 49,600 101,100
Functional Food 14,031 14,492 7,400 14,900
Net Sales 101,448 114,716 57,000 116,000

page-top